Trial Search Results

High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma

To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Intervention(s):

  • Procedure: high dose chemotherapy then autologous hematopoietic cell transplant

Phase:

Phase 2

Eligibility


Inclusion Criteria:- received cytoreduction prior to transplant

- adequate organ function

Exclusion Criteria:- previous transplant

- smoldering MM or benign monoclonal gammopathy

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
6507230822
Not Recruiting